Omico welcomes the Federal Government’s significant $143.4 million investment in world-leading precision oncology programs—the Zero Childhood Cancer Program and PrOSPeCT—that support children and adults diagnosed with challenging cancers.
PrOSPeCT has been instrumental in providing Australians with advanced, incurable, and poor prognosis cancer diagnoses the ability to receive precision oncology and is a critical initiative advancing cancer care in this country.
Ian Black, CEO, of Omico says” We are extremely pleased that the PrOSPeCT initiative will continue delivering precision oncology to Australians facing the toughest cancer diagnoses. This investment ensures the vital infrastructure we’ve established remains available to more people, offering access to comprehensive genomic profiling and matched therapies at no cost to patients. It is a commitment to patients, families, and Australia’s leadership in cutting-edge cancer care. We thank the Minister for recognising the impact of this work and the importance of ensuring its continuation.”
Since 2016, Omico’s programs have provided more than 22,300 Australians access to precision oncology innovations, with referrals from over 1,300 clinicians nationwide. Beyond transforming patient care, Omico has supported more than 90 oncology clinical trials—expanding Australia’s research capabilities, attracting international investment, and offering patients and families treatment options that would otherwise be out of reach.
FINDING THE HER2 LOW PATIENT: A PODCAST WITH PROF. FRAN BOYLE AND DR. SANJEEV KUMAR
Professor David Thomas, Chief Science and Strategy Officer at Omico and Director of the Centre of Molecular Oncology, UNSW, says “Investing in Omico is an investment in both the health and economy of Australia. Over 8 years we have built systems, a national network, and know-how, generated vital evidence, stimulated economic growth, and most importantly, changed lives. But our work is far from done. With this support, we can continue to expand access to precision oncology for Australians with challenging cancers. Beyond this, we look forward to progressing conversations with government and industry to take the next step—making precision oncology a routine part of cancer care.”
Continuing our commitment to Australians with complex and advanced cancers is vital—not only for the patients and families who rely on these innovations but also for advancing research that drives the future of cancer care. We are honoured that the ground-breaking work behind PrOSPeCT and the Zero Childhood Cancer Program will continue, improving outcomes for Australians. Our focus remains clear: embedding precision oncology into a sustainable cancer care model and ensuring advanced healthcare solutions become standard patient care.
Source: OMICO
